MTD:NYE-Mettler-Toledo International Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 1423.18

Change

+0.59 (+0.04)%

Market Cap

USD 10.87B

Volume

0.08M

Analyst Target

USD 865.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Mettler-Toledo International Inc is engaged in the supply of precision instruments and services. It is a provider of weighing instruments for use in laboratory, industrial and food retailing applications.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+1.76 (+0.65%)

USD 192.25B
IQV IQVIA Holdings Inc

+0.30 (+0.13%)

USD 45.24B
A Agilent Technologies Inc

+0.92 (+0.67%)

USD 39.45B
LH Laboratory Corporation of Amer..

+1.07 (+0.49%)

USD 18.80B
DGX Quest Diagnostics Incorporated

-0.38 (-0.25%)

USD 17.18B
QGEN Qiagen NV

+0.79 (+1.73%)

USD 9.81B
CRL Charles River Laboratories

+4.29 (+2.21%)

USD 9.70B
VNRX Volitionrx Ltd

-0.02 (-2.86%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.02 (-1.77%)

USD 0.06B
TMO Thermo Fisher Scientific Inc

-2.99 (-0.49%)

N/A

ETFs Containing MTD

MCSE Martin Currie Sustainable.. 5.12 % 0.00 %

+0.07 (+0.00%)

N/A
EPRE 4.58 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.39 % 0.00 %

+0.10 (+0.00%)

N/A
BMED BlackRock Future Health E.. 2.35 % 0.00 %

+0.29 (+0.00%)

USD 4.21M
GLUG:SW L&G Clean Water UCITS ETF.. 2.31 % 0.00 %

+0.04 (+0.00%)

USD 0.45B
XMLC:F L&G Clean Water UCITS ETF 2.27 % 0.00 %

+0.16 (+0.00%)

N/A
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.19 % 0.00 %

+0.10 (+0.00%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.19 % 0.00 %

N/A

N/A
XLVE:CA Mulvihill U.S. Health Car.. 1.82 % 0.00 %

N/A

N/A
EDGE-U:CA Evolve Innovation Index F.. 1.51 % 0.00 %

N/A

N/A
HECO 0.00 % 0.95 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+2.25 (+0.00%)

USD 7.71B
QRI:CA 0.00 % 1.06 %

N/A

N/A
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.60 %

+0.47 (+0.00%)

CAD 0.04B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.01B
YXM.B:CA 0.00 % 0.69 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.38 (+0.00%)

CAD 0.27B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
XMLC:XETRA L&G Clean Water UCITS ETF 0.00 % 0.00 %

+0.26 (+0.00%)

USD 0.42B
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.33% 100% F 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.33% 100% F 77% C+
Trailing 12 Months  
Capital Gain 16.89% 92% A 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.89% 85% B 60% D-
Trailing 5 Years  
Capital Gain 116.69% 100% F 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.69% 100% F 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 17.15% 92% A 81% B-
Dividend Return 17.15% 92% A 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.04% 38% F 33% F
Risk Adjusted Return 55.23% 85% B 74% C
Market Capitalization 10.87B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.90 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.